Silence Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Silence Therapeutics has a total shareholder equity of £94.5M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £169.4M and £74.9M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£128.99m |
| Equity | UK£94.52m |
| Total liabilities | UK£74.87m |
| Total assets | UK£169.38m |
Recent financial health updates
Recent updates
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
Oct 04
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 18Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
Jun 17Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
May 21Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12New finance chief for Silence Therapeutics
Jan 06Financial Position Analysis
Short Term Liabilities: SLN's short term assets (£157.5M) exceed its short term liabilities (£16.9M).
Long Term Liabilities: SLN's short term assets (£157.5M) exceed its long term liabilities (£58.0M).
Debt to Equity History and Analysis
Debt Level: SLN is debt free.
Reducing Debt: SLN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SLN has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 31.7% each year.